Next Article in Journal
Antibiotic Usage in Patients Having Undergone Caesarean Section: A Three-Level Study in Benin
Previous Article in Journal
Antimicrobial Susceptibility of Enterococcus Isolates from Cattle and Pigs in Portugal: Linezolid Resistance Genes optrA and poxtA
Case Report

Salphage: Salvage Bacteriophage Therapy for Recalcitrant MRSA Prosthetic Joint Infection

1
Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
2
Department of Orthopedic Surgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA
3
Department of Pharmacy, University of Maryland Medical Center, Baltimore, MD 21201, USA
4
Department of Ecology and Evolutionary Biology, Yale University, New Haven, CT 06520, USA
5
Yale Center for Phage Biology & Therapy, Yale University, New Haven, CT 06520, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Aneta Skaradzińska and Anna Nowaczek
Antibiotics 2022, 11(5), 616; https://doi.org/10.3390/antibiotics11050616
Received: 31 March 2022 / Revised: 27 April 2022 / Accepted: 2 May 2022 / Published: 4 May 2022
Prosthetic joint infections are a devastating complication of joint replacement surgery. Consequently, novel therapeutics are needed to thwart the significant morbidity and enormous financial ramifications that are associated with conventional treatments. One such promising adjuvant therapeutic is bacteriophage therapy given its antibiofilm activity and its ability to self-replicate. Herein we discuss the case of a 70-year-old female who had a recalcitrant MRSA prosthetic knee and femoral lateral plate infection who was successfully treated with adjuvant bacteriophage therapy. Moreover, this case discusses the importance of propagating bacteriophage therapeutics on bacteria that are devoid of toxins and the need to ensure bacteriophage activity to all bacterial morphologies. Overall, this case reinforces the potential benefit of using personalized bacteriophage therapy for recalcitrant prosthetic joint infections, but more translational research is needed to thereby devise effective, reproducible clinical trials. View Full-Text
Keywords: bacteriophage therapy; Staphylococcus aureus; prosthetic joint infection; cell surface receptor; transaminitis bacteriophage therapy; Staphylococcus aureus; prosthetic joint infection; cell surface receptor; transaminitis
Show Figures

Figure 1

MDPI and ACS Style

Doub, J.B.; Ng, V.Y.; Lee, M.; Chi, A.; Lee, A.; Würstle, S.; Chan, B. Salphage: Salvage Bacteriophage Therapy for Recalcitrant MRSA Prosthetic Joint Infection. Antibiotics 2022, 11, 616. https://doi.org/10.3390/antibiotics11050616

AMA Style

Doub JB, Ng VY, Lee M, Chi A, Lee A, Würstle S, Chan B. Salphage: Salvage Bacteriophage Therapy for Recalcitrant MRSA Prosthetic Joint Infection. Antibiotics. 2022; 11(5):616. https://doi.org/10.3390/antibiotics11050616

Chicago/Turabian Style

Doub, James B., Vincent Y. Ng, Myounghee Lee, Andrew Chi, Alina Lee, Silvia Würstle, and Benjamin Chan. 2022. "Salphage: Salvage Bacteriophage Therapy for Recalcitrant MRSA Prosthetic Joint Infection" Antibiotics 11, no. 5: 616. https://doi.org/10.3390/antibiotics11050616

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop